Trega Biosciences (TRGA), formerly HPIP Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trega Biosciences (TRGA), formerly HPIP

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: E.J. Neitz Jr who wrote (4)	12/3/1996 7:19:00 PM
From: E.J. Neitz Jr	of 152

HPIP Reports HP228 is Safe in Study 12-3-96 Reuters San Diego, Dec 3 (Reuter)- Houghton Pharmacuticals Inc said on Tuesday a 17 patient dose tolerance test of its drug, HP 228, for use by obese , type II diabetics showed no significant safety concerns in recipients. In a statement, the company said it would start additional trials, including those with longer dosing periods in the diabetic population. HP 228 is a cytokine regulating agent. In preclinical studies, compounds in its class showed potent anti-inflamatory and metabolic effects when used with a unique receptor pathway. Reuter Rtr 10:09 12-03-96

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next